Photo by nci from unsplash
Dual antiplatelet therapy (DAPT) has been the mainstay of antithrombotic management for acute coronary syndrome (ACS). Approximately 5-10% of patients experience recurrent events despite standard treatment, and there is an… Click to show full abstract
Dual antiplatelet therapy (DAPT) has been the mainstay of antithrombotic management for acute coronary syndrome (ACS). Approximately 5-10% of patients experience recurrent events despite standard treatment, and there is an unmet demand for secondary cardiovascular prevention in the post-ACS setting
Keywords:
efficacy safety;
dual antiplatelet;
antiplatelet therapy;
therapy;
comparative efficacy
Journal Title: Journal of the American College of Cardiology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the American College of Cardiology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!